[go: up one dir, main page]

PE20110928A1 - Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2 - Google Patents

Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2

Info

Publication number
PE20110928A1
PE20110928A1 PE2011001208A PE2011001208A PE20110928A1 PE 20110928 A1 PE20110928 A1 PE 20110928A1 PE 2011001208 A PE2011001208 A PE 2011001208A PE 2011001208 A PE2011001208 A PE 2011001208A PE 20110928 A1 PE20110928 A1 PE 20110928A1
Authority
PE
Peru
Prior art keywords
ccr2
antagonists
ilcarbamoil
benzamide
pyridin
Prior art date
Application number
PE2011001208A
Other languages
English (en)
Inventor
Xuqing Zhang
Heather Rae Hufnagel
Cuifen Hou
Dana L Johnson
Zhihua Sui
Barry Fegely
David Breslin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110928(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20110928A1 publication Critical patent/PE20110928A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)

Abstract

REFERIDA A UN COMPUESTO CICLOHEXANOL DE FORMULA (I), DONDE R1 ES PIRIDILO, PIRIDIL-N-OXIDO, INDOLILO, ENTRE OTROS; R2 ES ALQUILO C1-C4, NH2, NO2, ENTRE OTROS; R3 ES H, F, CF3, ENTRE OTROS; R4 ES H, O-ALQUILO C1-C4, F. SON COMPUESTOS PREFERIDOS: N-({1-[4-HIDROXI-4-(6-METOXI-PIRIDIN-3-IL)-CICLOHEXIL]-AZETIDIN-3-ILCARBAMOIL}-METIL)-3-TRIFLUOROMETIL-BENZAMIDA, N-({1-[4-HIDROXI-4-(6-METOXI-1-OXI-PIRIDIN-3-IL)-CICLOHEXIL]-AZETIDIN-3-ILCARBAMOIL}-METIL)-3-TRIFLUOROMETIL-BENZAMIDA, N-({1-[4-(6-ETOXI-PIRIDIN-3-IL)-4-HIDROXI-CICLOHEXIL]-AZETIDIN-3-ILCARBAMOIL}-METIL)-3-TRIFLUOROMETIL-BENZAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR 2 DE CITOCINA QUIMIOATRAYENTE (CCR2) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES OBSTRUCTIVAS CRONICAS PULMONARES, UVEITIS, ARTRITIS REUMATOIDE, ENTRE OTRAS
PE2011001208A 2008-12-10 2009-12-09 Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2 PE20110928A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12127208P 2008-12-10 2008-12-10
US16729509P 2009-04-07 2009-04-07

Publications (1)

Publication Number Publication Date
PE20110928A1 true PE20110928A1 (es) 2012-01-05

Family

ID=41510894

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001208A PE20110928A1 (es) 2008-12-10 2009-12-09 Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2

Country Status (28)

Country Link
US (1) US8450304B2 (es)
EP (1) EP2376475B1 (es)
JP (1) JP5782381B2 (es)
KR (1) KR20110094325A (es)
CN (1) CN102317278B (es)
AR (1) AR074583A1 (es)
AU (1) AU2009324723B2 (es)
BR (1) BRPI0923237A2 (es)
CA (1) CA2745969C (es)
CL (1) CL2011001427A1 (es)
CO (1) CO6331470A2 (es)
CR (1) CR20110381A (es)
EA (1) EA018997B1 (es)
EC (1) ECSP11011124A (es)
ES (1) ES2555004T3 (es)
HN (1) HN2011001606A (es)
IL (1) IL213250A0 (es)
MX (1) MX2011006226A (es)
NI (1) NI201100117A (es)
NZ (1) NZ593172A (es)
PA (1) PA8853001A1 (es)
PE (1) PE20110928A1 (es)
SG (1) SG171998A1 (es)
SV (1) SV2011003944A (es)
TW (1) TW201033204A (es)
UY (1) UY32312A (es)
WO (1) WO2010068663A1 (es)
ZA (1) ZA201105056B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110928A1 (es) 2008-12-10 2012-01-05 Janssen Pharmaceutica Nv Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2
EP2419417B1 (en) * 2009-04-16 2015-03-25 Janssen Pharmaceutica NV 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
AU2010236346B2 (en) 2009-04-17 2015-01-22 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of CCR2
CN102459226B (zh) * 2009-04-17 2014-09-17 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
TW201211027A (en) * 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
AU2011268375B2 (en) 2010-06-17 2015-02-05 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
WO2013060865A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
PT3297438T (pt) 2015-05-21 2022-01-25 Chemocentryx Inc Moduladores de ccr2
CN111712242B (zh) 2017-09-25 2023-11-24 凯莫森特里克斯股份有限公司 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
CN107793404A (zh) * 2017-11-07 2018-03-13 全椒先奇医药科技有限公司 一种治疗缺血性脑损伤药物组合物及其应用
AU2019205784B2 (en) 2018-01-08 2024-07-25 Chemocentryx, Inc. Methods of treating solid tumors with CCR2 antagonists
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
AU734892B2 (en) 1997-06-18 2001-06-28 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
CA2378499A1 (en) * 1999-08-04 2001-02-15 Teijin Limited Cyclic amine ccr3 antagonists
US6245799B1 (en) * 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
EP1228065A1 (en) 1999-11-08 2002-08-07 Wyeth (indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
CA2432369A1 (en) * 2000-12-20 2002-08-08 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
UA87449C2 (ru) * 2002-11-27 2009-07-27 Инсайт Корпорейшн Производные 3-аминопиролидина как модуляторы рецепторов хемокина
US7834021B2 (en) * 2002-11-27 2010-11-16 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
CA2550596C (en) 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
EP1802602A1 (en) * 2004-09-28 2007-07-04 Janssen Pharmaceutica N.V. Substituted dipiperdine ccr2 antagonists
US20060073592A1 (en) * 2004-10-06 2006-04-06 Wendell Sun Methods of storing tissue matrices
PA8653301A1 (es) * 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
GB0513747D0 (en) 2005-07-06 2005-08-10 Merck Sharp & Dohme Therapeutic compounds
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US20070197590A1 (en) 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
PE20110928A1 (es) 2008-12-10 2012-01-05 Janssen Pharmaceutica Nv Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2
EP2419417B1 (en) * 2009-04-16 2015-03-25 Janssen Pharmaceutica NV 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
CN102459226B (zh) 2009-04-17 2014-09-17 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
AU2010236346B2 (en) * 2009-04-17 2015-01-22 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of CCR2

Also Published As

Publication number Publication date
ECSP11011124A (es) 2011-07-29
ZA201105056B (en) 2012-12-27
TW201033204A (en) 2010-09-16
CO6331470A2 (es) 2011-10-20
UY32312A (es) 2010-06-30
AR074583A1 (es) 2011-01-26
CA2745969A1 (en) 2010-06-17
KR20110094325A (ko) 2011-08-23
EP2376475B1 (en) 2015-09-02
PA8853001A1 (es) 2010-07-27
NI201100117A (es) 2012-06-13
CN102317278A (zh) 2012-01-11
WO2010068663A1 (en) 2010-06-17
MX2011006226A (es) 2011-06-24
EP2376475A1 (en) 2011-10-19
CR20110381A (es) 2011-11-10
NZ593172A (en) 2013-03-28
CN102317278B (zh) 2016-01-06
ES2555004T3 (es) 2015-12-28
US20100144695A1 (en) 2010-06-10
US8450304B2 (en) 2013-05-28
SV2011003944A (es) 2011-07-21
CA2745969C (en) 2017-04-25
CL2011001427A1 (es) 2011-10-21
SG171998A1 (en) 2011-07-28
BRPI0923237A2 (pt) 2019-09-24
EA201170795A1 (ru) 2011-12-30
EA018997B1 (ru) 2013-12-30
HN2011001606A (es) 2014-02-03
AU2009324723A1 (en) 2010-06-17
IL213250A0 (en) 2011-07-31
JP5782381B2 (ja) 2015-09-24
JP2012511582A (ja) 2012-05-24
AU2009324723B2 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
PE20110928A1 (es) Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20141375A1 (es) Activadores de glucoquinasa
PE20090434A1 (es) Derivados de sulfonil amida como inhibidores de quinasas
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20090772A1 (es) Derivados de bencimidazol
PE20140836A1 (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
AR072490A1 (es) 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20081779A1 (es) Derivados de nicotinamida
PE20080061A1 (es) Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20120812A1 (es) Compuestos vinil indazolilo
PE20110329A1 (es) Agonistas del receptor acoplado a la proteina g piperidinilo
PE20080525A1 (es) Derivados de imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo como moduladores del receptor canabinoide 1 (cb1r)
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
NO20074287L (no) Pyrazin-2-karboksamidderivater som mGluR5 antagonister
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed